Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Embraer Q4 2025 Earnings Call - Tariff Exemption Clears Path to Upside as Backlog Hits $31.6bn
Embraer closed 2025 with record revenue, a $31.6 billion backlog and momentum across commercial, executive, defense and services. Management beat financial expectations, delivered operational targets,...
- Record backlog: company-wide backlog reached $31.6 billion in Q4 2025, up about 20% year over year, with roughly $20 billion of customer options not included in backlog representing material upside.
- E2 momentum: commercial aviation booked 157 E2 new orders plus 140 options in 2025, lifting the commercial backlog to $14.5 billion and a 2.8-to-1 book-to-bill ratio for the division.
- Executive aviation peak quarter: Q4 revenues for executive aviation reached about $750 million, with 53 business jets delivered in the quarter, the highest quarterly tally ever.
- +14 more takeaways
Evaxion Full Year 2025 Earnings Call - Platform validated by MSD option and strong EVX-01 2-year data
Evaxion spent 2025 turning platform promise into tangible validation. The company secured an MSD option exercise on EVX-B3, won a Gates Foundation collaboration, and presented compelling EVX-01 phase ...
- MSD exercised its option for EVX-B3, marking an industry in-licensing validation of an infectious disease candidate discovered via Evaxion’s AI platform.
- MSD chose not to exercise its option on EVX-B2 (gonorrhea); Evaxion retained global rights and reports strong preclinical data and external interest.
- EVX-01 personalized neoantigen cancer vaccine reported 2-year phase 2 data: 75% objective response rate, 25% complete response rate, and 92% of responders remained in response at 24 months.
- +12 more takeaways
Genesco Fourth Quarter Fiscal 2026 Earnings Call - Journeys-led rebound masks Schuh reset, leaving FY27 sales flat while margins recover
Genesco closed fiscal 2026 with a clear story: Journeys is firing on all cylinders and carrying the quarter, but Schuh’s promotional reset and winding down of licenses will mute top-line growth in fis...
- Q4 revenue $800 million, up 7% year-over-year; comparable sales +9% (stores +9%, direct +8%).
- Journeys led Q4 with +12% comps, building on +14% in the prior-year quarter; Journeys outpaced the footwear market and grew total customers in December and January.
- Adjusted diluted EPS for Q4 was $3.74 versus $3.26 last year; full-year adjusted diluted EPS was $1.45 versus $0.94 the prior year.
- +12 more takeaways
Methanex Corporation Q4 2025 Earnings Call - Middle East supply shocks lift spot prices, company prioritizes debt paydown
Methanex closed 2025 with steady production, a $331/ton average realized price in Q4, and Adjusted EBITDA of $186 million, but an adjusted net loss of $11 million. Management is flagging a clear pivot...
- Q4 2025 headline metrics: average realized price $331/ton, produced sales ~2.4 million tons, Adjusted EBITDA $186 million, adjusted net loss $11 million.
- Q1 2026 realized price guidance estimated between $330 and $340 per ton, and management expects slightly higher Adjusted EBITDA in Q1 versus Q4.
- 2026 equity production guide is approximately 9 million tons, with regional rough breakdowns: North America a little over 6 million tons, Chile 1.3–1.4 million, Egypt 0.5–0.6 million, Trinidad ~0.8 million, New Zealand under 0.5 million.
- +12 more takeaways
Methode Electronics Q3 2026 Earnings Call - EBITDA Guidance Cut Amid Mexico Execution Issues, Offset by $120M Data Center Run Rate
Methode reported a soft quarter, squeezing profitability but still generating cash as it leans into industrial power and data center opportunities. Revenue was about $233.7 million, adjusted EBITDA wa...
- Q3 net sales were $233.7 million, a 3% decline year over year, reflecting softer North American automotive volumes and an interface segment program roll-off.
- Adjusted EBITDA for the quarter was $7.3 million, down about $5.0 million year over year; adjusted net loss was $13.1 million and adjusted loss per diluted share was $0.37.
- Management narrowed FY26 net sales guidance to $950 million to $1.0 billion, raising the low end largely due to a foreign exchange tailwind of approximately $30 million versus prior assumptions.
- +11 more takeaways
Granite Ridge Resources Q4 2025 Earnings Call - Pivot to Permian operator partnerships and a stated path to free cash flow in 2027
Granite Ridge reported another scaling year, with Q4 average daily production at 35.1k BOE per day and full-year average near 32k BOE per day, while adjusted EBITDAX landed at about $70 million in Q4 ...
- Company strategy pivoted from diversified non-operated investments to Permian-focused operated partnerships, led by Admiral Permian Resources, to capture high-return, short-cycle inventory.
- Q4 production averaged 35.1k BOE per day, full-year average ~31,984 BOE per day, representing ~27%-28% year-over-year growth; management expects 2026 average production of ~35,000 BOE per day (34k-36k guidance).
- Adjusted EBITDAX was approximately $69.5m in Q4 and $315m for full-year 2025; operating cash flow was $64.5m in Q4 and $296.4m for the year.
- +12 more takeaways
Kingstone Companies Fourth Quarter and Full Year 2025 Earnings Call - Record Profitability, Strong Underlying Metrics, 2026 Guided for CAT Normalization
Kingstone closed 2025 with its most profitable quarter and year in company history, driven by rapid premium growth, deeper retention of risk and a sharp improvement in underwriting performance. Q4 net...
- Q4 net income $14.8 million, diluted EPS $1.03, diluted operating EPS $1.08, GAAP net combined ratio 64.2, annualized ROE 51%.
- Full year 2025 net income $40.8 million, diluted EPS $2.88 (up 95%), return on equity 43%; most profitable year in company history.
- Direct premiums written: Q4 $82.8 million (up 14%); full year $277.8 million (up 15%); New York personal lines policies in force up over 7%.
- +15 more takeaways
Nutex Health Q4 2025 Earnings Call - CMS-driven IDR true-up crimps Q4 but core operations, cash flow, and IDR win rates show material improvement
Nutex Health reported a banner 2025 on a full-year basis, with revenue leaping 82% to $875.3 million and adjusted EBITDA surging to $259.6 million. The quarter looked ugly on headline comparisons afte...
- Full-year 2025 revenue grew 82% to $875.3 million from $479.9 million in 2024, driven by higher acuity claims and IDR recoveries.
- Adjusted EBITDA jumped 152.6% to $259.6 million for 2025, reflecting improved margins and arbitration-related revenue recognition adjustments.
- Net income was $70.8 million for 2025, which includes a one-time noncash stock-based compensation charge of $117 million tied to earnout shares for under-construction hospitals.
- +15 more takeaways
NewLake Capital Partners Q4 2025 Earnings Call - Strong Balance Sheet, Waiting on Rescheduling to Reopen Capital Markets
NewLake reported steady full-year 2025 results in a tough cannabis environment, producing $51.1 million of revenue and $43.8 million of AFFO, or $2.09 per share, and paying $1.72 per share in dividend...
- Full-year 2025 results: $51.1 million total revenue and $43.8 million AFFO, or $2.09 per share, a slight year-over-year increase in a tough market.
- Q4 2025 results: $12.3 million revenue, $10.6 million AFFO, or $0.51 per share; quarterly AFFO payout ratio was 85%.
- Dividends: full-year aggregate dividends were $1.72 per share, an AFFO payout ratio of 82%; board declared Q1 2026 cash dividend of $0.43 per share payable April 15, 2026.
- +12 more takeaways
Quanex Building Products Corporation Q1 2026 Earnings Call - Monterrey Plant Stabilized, Full-Year Adjusted EBITDA Guided to $240M-$245M
Quanex delivered a seasonally weak Q1 that largely tracked management expectations, but the call was dominated by two clear themes. First, the operational issue at the Monterrey, Mexico hardware plant...
- Monterrey, Mexico hardware plant operational issue addressed and considered stable; management expects no further updates and said prior incremental costs were temporary.
- Company guidance for fiscal 2026: net sales $1.84B-$1.87B and approximately $240M-$245M in adjusted EBITDA.
- First quarter consolidated net sales were $409.1M, up 2.3% year-over-year, driven mainly by foreign exchange translation and tariff pass-through.
- +13 more takeaways